Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Kodiak Sciences Inc - Common Stock
(NQ:
KOD
)
41.66
+0.09 (+0.20%)
Streaming Delayed Price
Updated: 10:12 AM EDT, Aug 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Kodiak Sciences Inc - Common Stock
< Previous
1
2
3
4
5
6
Next >
Kodiak CFO Sells $1 Million in Stock as Shares Surge 650%. What Investors Should Know
↗
June 09, 2026
This clinical-stage biotech focused on retinal therapies reported a notable insider sale amid a year of exceptional stock performance.
Via
The Motley Fool
Topics
Regulatory Compliance
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase
↗
May 17, 2026
Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally
↗
May 17, 2026
This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials.
Via
The Motley Fool
Topics
Regulatory Compliance
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares
↗
May 17, 2026
Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline.
Via
The Motley Fool
On Tuesday, there are stocks with unusual volume. Let's take a look.
↗
March 31, 2026
Via
Chartmill
Which stocks are gapping on Friday?
↗
March 27, 2026
Via
Chartmill
Kodiak Sciences Stock Is Surging Friday: What's Driving The Action?
↗
March 27, 2026
Kodiak Sciences Inc (NASDAQ: KOD) shares are trading higher Friday after positive Phase 3 GLOW2 results for Zenkuda in diabetic retinopathy.
Via
Benzinga
Top movers analysis one hour before the close of the markets on 2026-03-26: top gainers and losers in today's session.
↗
March 26, 2026
Via
Chartmill
Here are the top movers in Thursday's session.
↗
March 26, 2026
Via
Chartmill
Thursday's session: gap up and gap down stocks
↗
March 26, 2026
Via
Chartmill
Kodiak Sciences Surges 19% as Phase 3 GLOW2 Trial Delivers Vital Win for Diabetic Retinopathy Treatment
March 26, 2026
On March 26, 2026, Kodiak Sciences (Nasdaq: KOD) saw its shares ignite, surging 19% in heavy trading following the announcement of overwhelmingly positive topline results from its Phase 3 GLOW2 study....
Via
MarketMinute
These stocks that are showing activity before the opening bell on Thursday.
↗
March 26, 2026
Via
Chartmill
Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing
↗
March 09, 2026
This clinical-stage biotech targets retinal diseases with late-stage drug candidates and a focused pipeline in ophthalmology.
Via
The Motley Fool
Topics
Regulatory Compliance
Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing
↗
March 06, 2026
This clinical-stage biotech develops precision oncology therapies and diagnostics targeting unmet needs in breast and ovarian cancer.
Via
The Motley Fool
Topics
Regulatory Compliance
Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing
↗
March 05, 2026
This clinical-stage biotech develops small-molecule therapies for liver and metabolic diseases, targeting unmet needs in NASH and obesity.
Via
The Motley Fool
Topics
Regulatory Compliance
Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing
↗
March 04, 2026
This clinical-stage biotech develops targeted cancer therapies, leveraging strategic partnerships and a differentiated oncology pipeline.
Via
The Motley Fool
Topics
Regulatory Compliance
Kodiak Sciences Stock Up 480% as One Fund Discloses $53 Million Buy
↗
February 23, 2026
Focused on retinal disease therapeutics, this clinical-stage biotech advances drug candidates for vision-threatening conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead
↗
February 19, 2026
Focused on retinal disease therapies, Kodiak Sciences leads with clinical-stage candidates targeting major unmet needs in ophthalmology.
Via
The Motley Fool
Topics
Regulatory Compliance
These stocks are gapping in today's session
↗
December 17, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday.
Via
Chartmill
This Coinbase Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday
↗
October 24, 2025
Via
Benzinga
Gapping stocks in Monday's session
↗
October 20, 2025
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via
Chartmill
WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday
↗
October 20, 2025
Via
Benzinga
Topics
Artificial Intelligence
10 Health Care Stocks Whale Activity In Today's Session
↗
October 06, 2025
Via
Benzinga
Ameresco, Lithium Americas, Kodiak Sciences And Other Big Stocks Moving Higher On Thursday
↗
September 25, 2025
U.S. stocks were lower, with the Nasdaq Composite falling more than 100 points on Thursday.
Via
Benzinga
Topics
Stocks
Top stock movements in today's session.
↗
September 22, 2025
Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.
Via
Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
↗
September 22, 2025
Via
Benzinga
PROS Holdings, MBX Biosciences, Metsera, Anywhere Real Estate And Other Big Stocks Moving Higher On Monday
↗
September 22, 2025
Via
Benzinga
Jim Cramer: Kodiak Sciences Is A 'Pure Spec' Stock, Recommends Buying This Utilities Stock
↗
August 27, 2025
Kodiak Sciences posted a second-quarter loss of $1.03 per share, compared to market estimates of a loss of $1.02 per share.
Via
Benzinga
Kimball Electronics Posts Better-Than-Expected Earnings, Joins Terawulf, Dlocal, Equinox Gold And Other Big Stocks Moving Higher On Thursday
↗
August 14, 2025
Via
Benzinga
Kodiak Sciences Beats Q2 Loss Estimates
↗
August 13, 2025
Via
The Motley Fool
Topics
Intellectual Property
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
